Search results
Description. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization. This medicine is also used to treat children with symptomatic heart failure. Valsartan is an angiotensin II receptor blocker (ARB).
18 paź 2023 · Our systematic review suggests that sacubitril-valsartan benefits patients with ESKD with HFrEF and HFmrEF by improving LVEF without increasing the risk of hyperkalemia, hypotension, or angioedema compared to standard care.
Sacubitril-valsartan was associated with lower risks of death and hospitalization compared with ACE/ARB in a heterogeneous cohort of patients with systolic HF. However, our finding that outcomes with sacubitril-valsartan and ACE/ARBs were similar in black patients warrants further evaluation.
Objective: To investigate whether hypotensive patients diagnosed with heart failure and reduced ejection fraction (HFrEF) might benefit from angiotensin receptor-neprilysin inhibitors (ARNis) in real-world practice because patients with baseline systolic blood pressure (SBP) of less than 100 mm Hg have been excluded from landmark trials.
This randomized clinical trial evaluates the use of sacubitril/valsartan therapy compared with valsartan alone in US patients with advanced chronic heart
27 gru 2018 · Lek sakubitryl/walsartan, mimo że jest nowym produktem na rynku farmaceutycznym, jest coraz częściej i chętniej stosowany u chorych z objawową NS i rEF lewej komory. Badania kliniczne i praktyka wykazały, że sakubitryl/walsartan jest lekiem bezpiecznym i dobrze tolerowanym u chorych z NS.
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes associated with the use of this therapy.
